DHAPQ: A New Cornerstone in the Global Fight Against Malaria
Table of Contents
A highly effective treatment, dihydroartemisinin-piperaquine (DHAPQ), is rapidly becoming a vital tool in combating malaria, particularly in Africa and Asia. This artemisinin-based combination therapy (ACT) offers a simplified, three-day regimen that significantly reduces treatment failure and reinfection rates, offering renewed hope in the ongoing battle against this deadly disease.
The Burden of Malaria and the Need for Innovation
Malaria remains one of the world’s most devastating infectious diseases, disproportionately impacting children under five in sub-Saharan Africa. According to data from Our World in Data, malaria is a leading cause of child mortality across much of the region. Left untreated or inadequately treated, uncomplicated malaria can quickly escalate to severe illness and death. “DHAPQ helps address critical gaps in malaria treatment by providing a well-tolerated, easy-to-administer therapy,” a senior official stated.
How DHAPQ Works: A Two-Pronged Approach
DHAPQ combines two powerful medications: dihydroartemisinin and piperaquine. Dihydroartemisinin acts swiftly to eliminate parasites from the bloodstream, while piperaquine provides a longer-lasting effect, eradicating residual parasites and offering protection against reinfection for several weeks post-treatment. This complementary action is key to DHAPQ’s success. Researchers developed DHAPQ as a fixed-dose combination to ensure patients receive the optimal ratio of both drugs with each dose, addressing previous challenges with drug resistance and complex dosing schedules.
Clinical Success and Global Recognition
Extensive clinical trials have demonstrated DHAPQ’s high efficacy and excellent tolerability. The therapy has consistently outperformed other ACTs in preventing recurrent infections, thanks to its extended post-treatment protection. The World Health Organization (WHO) now recommends DHAPQ as a first-line treatment for uncomplicated Plasmodium falciparum malaria.
Ghana has already adopted DHAPQ as a second-line therapy, where it continues to demonstrate efficacy rates exceeding 90% in children under routine use. Further bolstering its credibility, DHAPQ is approved by the European Medicines Agency (EMA) under the trade name Eurartesim®.
Advancing Research and Expanding Access
Ongoing research, supported by funding from the EDCTP, continues to refine the use of DHAPQ. Clinical trials are focused on optimizing dosing, assessing safety, and understanding potential side effects, particularly in vulnerable populations like young children and individuals living with HIV. These studies have generated crucial data that have directly informed WHO recommendations and strengthened the evidence base for the safe and effective implementation of DHAPQ. [2], [3], [4]
Today, DHAPQ is widely deployed across Africa and Asia, and its integration into national malaria control programs, coupled with its consistent clinical success, solidifies its position as a cornerstone in the global fight against malaria.
